[{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"IC265","moa":"Syk","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"IACTA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"PUERTO RICO","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Pharmaleads","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"IC 800","moa":"Undisclosed","graph1":"Neurology","graph2":"IND Enabling","graph3":"IACTA Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Topical","sponsorNew":"IACTA Pharmaceuticals \/ IACTA Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"IACTA Pharmaceuticals \/ IACTA Pharmaceuticals"},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"US Army Medical Research Acquisition Activity","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"PUERTO RICO","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"IC 800","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"IACTA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical","sponsorNew":"IACTA Pharmaceuticals \/ US Army Medical Research Acquisition Activity","highestDevelopmentStatusID":"4","companyTruncated":"IACTA Pharmaceuticals \/ US Army Medical Research Acquisition Activity"}]